News Results for Glaxosmithkline (GSK)

DZ Bank today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1900p (from 2000p). Story provided by StockMarketWire.com Broker Forecasts data...

GlaxoSmithKline had completed the sale of Indian consumer healthcare assets including the Horlicks brands to Unilever, the companies said on Wednesday. The deal, first announced in December 2018,...

Oddo today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1530p (from 1830p). Story provided by StockMarketWire.com Broker Forecasts data...

Barclays Capital today reaffirms its underweight investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1450p (from 1550p). Story provided by StockMarketWire.com Broker...

Morgan Stanley today reaffirms its underweight investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1725p (from 1740p). Story provided by StockMarketWire.com Broker...

Emma Walmsley, Chief Executive Officer, exercised 62,036 shares in the company on the 17th February 2020 at a price of 0.00p. The Director now holds 779,263 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, exercised 62,036 shares in the company on the 17th February 2020 at a price of 0.00p. The Director now holds 779,263 shares. Story provided by...

Liberum Capital today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1840p (from 1930p). Story provided by StockMarketWire.com Broker Forecasts...

Societe Generale today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 2240p (from 2300p). Story provided by StockMarketWire.com Broker Forecasts...

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 2050p (from 2110p). Story provided by StockMarketWire.com Broker Forecasts data...

UBS today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1900p (from 1950p). Story provided by StockMarketWire.com Broker Forecasts data provided...

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1750p (from 1900p). Story provided by StockMarketWire.com Broker...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1600p (from 1650p). Story provided by StockMarketWire.com Broker Forecasts...

Barclays Capital today reaffirms its underweight investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1550p (from 1650p). Story provided by StockMarketWire.com Broker...

Jonathan Symonds, Chairman, bought 11,730 shares in the company on the 6th February 2020 at a price of 1705.00p. The Director now holds 14,995 shares representing 0.00% of the shares in issue....

Bryan Garnier today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1773p (from 1800p). Story provided by StockMarketWire.com Broker Forecasts...

Urs Rohner, Non Executive Director, bought 399 shares in the company on the 5th February 2020 at a price of 1800.00p. The Director now holds 9,499 shares representing 0.00% of the shares in issue....

Dr Vivienne Cox, Non Executive Director, received in lieu of fees/salary 295 shares in the company on the 5th February 2020 at a price of 1800.00p. The Director now holds 5,009 shares representing...

Jonathan Symonds, Chairman, bought 2,431 shares in the company on the 5th February 2020 at a price of 1800.00p. The Director now holds 3,265 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 399 shares in the company on the 5th February 2020 at a price of 1800.00p. The Director now holds 5,225 shares representing 0.00% of the shares in...

Pharmaceutical company GlaxoSmithKline reported a 30% rise in annual profit after it doubled of sales of its shingles vaccine, though if forecast weaker earnings in 2020. Pre-tax profit for the...

UBS today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1950p (from 1900p). Story provided by StockMarketWire.com Broker Forecasts data...

Liberum Capital today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1930p (from 1890p). Story provided by StockMarketWire.com Broker...

The FTSE 100 index traded down 0.5% at 7,607 heading into the close, despite new highs in US markets, as pharmaceutical stocks reversed their gains of earlier this week, weighing on the benchmark....

The FTSE 100 index traded down 0.5% at 7,607 heading into the close, despite new highs in US markets, as pharmaceutical stocks reversed their gains of earlier this week, weighing on the benchmark....

The FTSE 100 index traded down 0.5% at 7,607 heading into the close, despite new highs in US markets, as pharmaceutical stocks reversed their gains of earlier this week, weighing on the benchmark....

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1860p (from 1800p). Story provided by StockMarketWire.com Broker...

Emma Walmsley, Chief Executive Officer, has re-invested 1,754 shares in the company on the 13th January 2020 at a price of 1790.20p. The Director now holds 717,220 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, bought 1,371 shares in the company on the 14th January 2020 at a price of 1800.83p. The Director now holds 715,466 shares. Story provided by...

Societe Generale today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2300p (from 2200p). Story provided by StockMarketWire.com Broker...

Morgan Stanley today reaffirms its underweight investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1740p (from 1640p). Story provided by StockMarketWire.com Broker...

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1900p (from 1700p). Story provided by StockMarketWire.com Broker...

UK stocks opened moderately lower on Friday following a two-week winning streak triggered by Boris Johnson's election win. At 0854, the benchmark FTSE 100 index was down 15.37 points, or 0.2%, at...

GlaxoSmithKline confirmed that its ViiV Healthcare joint venture with Pfizer and Shionogi had received a so-called complete response letter from the US Food and Drug Administration rejecting an HIV...

Bryan Garnier today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1747p (from 1660p). Story provided by StockMarketWire.com Broker...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2000p (from 1850p). Story provided by StockMarketWire.com Broker...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1890p (from 1650p). Story provided by StockMarketWire.com Broker Forecasts...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1650p (from 1645p). Story provided by StockMarketWire.com Broker Forecasts...

UBS today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to buy (from neutral) and raised its price target to 1900p (from 1610p). Story provided by StockMarketWire.com Broker...

Liberum Capital today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1890p (from 1510p). Story provided by StockMarketWire.com Broker...

Barclays Capital today reaffirms its equal weight investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1650p (from 1600p). Story provided by StockMarketWire.com...

DZ Bank today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2000p (from 1850p). Story provided by StockMarketWire.com Broker Forecasts data...

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1800p (from 1700p). Story provided by StockMarketWire.com Broker...

UK equity markets ended the Wednesday session on the front foot as investors rallied around solid corporate results from several overseas earning companies and eyed a possible new rate cut by the...

Emma Walmsley, Chief Executive Officer, bought 1,470 shares in the company on the 11th October 2019 at a price of 1660.32p. The Director now holds 688,145 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, has re-invested 1,815 shares in the company on the 14th October 2019 at a price of 1712.00p. The Director now holds 689,960 shares. Story provided by...

UK stocks traded in a narrow range on Monday as investors grappled with ongoing Brexit uncertainty and lingering trade tension between the US and China. UK data on mortgage lending showed that...

UK stocks were slightly lower on Monday as investors grappled with ongoing Brexit uncertainty and lingering trade tension between the US and China. UK data on mortgage lending showed that mortgage...

UK stocks edged only slightly higher on Monday as investors grappled with ongoing Brexit uncertainty and lingering trade tension between the US and China. At 0858, the benchmark FTSE 100 index had...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1645p (from 1620p). Story provided by StockMarketWire.com Broker Forecasts...

Oil prices and stocks fell amid an apparent escalation in the US-China trade war. After China announced tariffs on US goods and president Trump threatened retaliation on Twitter. The FTSE 100 was...

As investors awaited to hear a speech from the US Federal Reserve chair Jerome Powell the FTSE 100 was stronger, gaining 0.8% to 7,185.34. US futures pointed to a slightly higher open on Wall...

UK stocks opened higher on Friday after Peppa Pig owner Entertainment One soared on a takeover bid, and investors awaited a speech from Fed Chair Jerome Powell that could shed more light on the...

GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal. 'The two-arm study met its primary objective and demonstrated a clinically meaningful overall...

UK share markets plunged farther and faster in late afternoon trade to close firmly in the red as a slow start to US trading failed to lift ongoing worries over US interest rate cuts following the...

UK share markets continue their decline at midday on Thursday as uncertainty over the outlook for US interest rate cuts following the release of minutes from the Federal Reserve's last policy...

UK stocks are falling on Thursday as the market digested the Wednesday's Federal Reserve July meeting minutes, which provided little clarity for future direction. At 08:58, the benchmark FTSE 100...

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments needed every year,...

GlaxoSmithKline said it had submitted an application for a drug that treats renal anaemia in patients with chronic kidney disease to the Japanese health regulator. 'Around 3.5 million patients in...

JP Morgan Cazenove today initiates coverage of GlaxoSmithKline PLC (LON:GSK) with a neutral investment rating and price target of 1700p. Story provided by StockMarketWire.com Broker Forecasts...

GlaxoSmithKline said it had completed its transaction with Pfizer to combine their consumer healthcare businesses into a joint venture. 'Now the deal has closed, our focus will be on completing...

GlaxoSmithKline's ViiV Healthcare joint venture with Pfizer said it had submitted a marketing authorisation application to the European Medicines Agency for its once-monthly injectable HIV-1...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1620p (from 1575p). Story provided by StockMarketWire.com Broker Forecasts...

Pharmaceutical company GlaxoSmithKline upgraded its annual earnings guidance after sales rose 7% in the second quarter. The company also announced that John Symonds, the current deputy chairman of...

UBS today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1610p (from 1630p). Story provided by StockMarketWire.com Broker Forecasts data...

Despite a weak US open, with the S&P 500 modestly lower in early trades, the FTSE 100 enjoyed decent gains on Monday. The positive performance coming as sterling took a tumble amid continuing...

The FTSE 100 was up by midday, advancing 0.2% to 7,520.77 after slipping into the red earlier. Investors apparently focused on the positive elements of China's latest growth figures, announced...

UK stocks opened slightly higher on Monday after the release of a mixed set of Chinese data that showed economic growth slowing but better-than-expected industrial output and retail sales. At...

GlaxoSmithKline said a clinical trial of its ovarian cancer treatment had met its primary goal. Niraparib, GSK's ovarian cancer drug demonstrated 'significant improvement' in progression free...

Emma Walmsley, Chief Executive Officer, has re-invested 19 shares in the company on the 11th July 2019 at a price of 1650.60p. The Director now holds 674,491 shares. NOTE: Re Share Reward Plan...

Emma Walmsley, Chief Executive Officer, bought 8 shares in the company on the 9th July 2019 at a price of 1636.22p. The Director now holds 674,472 shares. NOTE: Partnership Shares: Also awarded 8...

GlaxoSmithKline's ViiV Healthcare joint venture with Pfizer said its two-drug HIV treatment regime had met its primary goals after demonstrating a similar level of efficacy in controlling HIV-1 as...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1575p (from 1550p). Story provided by StockMarketWire.com Broker Forecasts...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer received marketing authorisation from the European Commission for its two-drug treatment for HIV. Marketing Authorisation for the...

The FTSE 100 endured a downbeat end to the week, falling more than 0.5% as the pharmaceutical sector came under some pressure. GlaxoSmithKline fell 1.3%, AstraZeneca was down 2% and Reckitt...

Morgan Stanley today initiates coverage of GlaxoSmithKline PLC (LON:GSK) with a underweight investment rating and price target of 1520p. Story provided by StockMarketWire.com Broker Forecasts...

Kepler Cheuvreux today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1540p (from 1440p). Story provided by StockMarketWire.com Broker...

A 1.1% rise in the FTSE 100 helped to put investors in a better mood at the end of the trading week. Helping the blue chip index was a 1.4% rise in the oil price which lifted shares in Royal Dutch...

The FTSE 100 traded 0.9% higher at 7,322 at 12.30pm on Friday, tracking gains in Asia and elsewhere in Europe, as investors warmed to the prospect of interest rate cuts to stave off global growth...

GlaxoSmithKline said that the Federal Drug Administration had approved two new methods for administering the company's asthma treatment. This approval would give healthcare professionals and...

GlaxoSmithKline said that the European Medicines Agency's Committee had issued a 'positive' opinion recommending two new methods for administering the company's asthma treatment. The agency...

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1550p (from 1520p). Story provided by StockMarketWire.com Broker Forecasts...

Bryan Garnier today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1660p (from 1710p). Story provided by StockMarketWire.com Broker Forecasts...

Sir Philip Hampton, Chairman, bought 2,790 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 54,241 shares representing 0.00% of the shares in issue. Story...

Manvinder Banga, Non Executive Director, bought 458 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 3,861 shares representing 0.00% of the shares in issue....

Dr Vivienne Cox, Non Executive Director, bought 339 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 3,971 shares representing 0.00% of the shares in issue....

Urs Rohner, Non Executive Director, bought 458 shares in the company on the 1st May 2019 at a price of 1568.00p. The Director now holds 8,522 shares representing 0.00% of the shares in issue....

Pharmaceuticals giant GlaxoSmithKline posted a rise in first-quarter earnings and reaffirmed its annual guidance following strong sales of its shingles vaccine and HIV treatments. Earnings per...

GlaxoSmithKline said its ViiV Healthcare joint venture had submitted a new drug application to the FDA seeking approval for two-drug HIV treatment regime. The monthly and injectable regimen...

Simon Dingemans, Financial Director, has re-invested 4,619 shares in the company on the 12th April 2019 at a price of 1565.60p. The Director now holds 99,648 shares representing 0.00% of the shares...

Emma Walmsley, Chief Executive Officer, has re-invested 1,856 shares in the company on the 15th April 2019 at a price of 1550.09p. The Director now holds 682,108 shares. Story provided by...

Global equities fell into the red after US President Donald Trump threatened tariffs on $11bn of European goods. At close, the FTSE 100 was 0.3% lower at 7,425. Elsewhere, European equities also...

The FTSE 100 was up a handful of points by midday at 7,455.71 with investors weighing the latest Brexit developments, as Theresa May headed to Berlin, as well as rising tensions between the EU and...

GlaxoSmithKline said its ViiV Healthcare joint venture with Pfizer received regulatory approval for its two-drug treatment for HIV from the US Food and Drug Administration. Dovato, a two-drug...

Weak economic data from the US and China weighed on global equities, as they added to concerns over global growth. The FTSE 100 fell 0.7% to 7,104. US jobs data was weaker than expected after...

Weak Chinese export data dialed up fears on global growth and sent the FTSE 100 sharply into reverse with US jobs numbers to come this afternoon. By midday the index of leading UK shares was down...

Shore Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by...

GlaxoSmithKline said Friday its ViiV Healthcare joint venture with Pfizer had recorded positive results from two clinical trials of an injectable two-drug regime for the treatment of HIV. The...

Britain's Serious Fraud Office said it had dropped investigations into individuals at GlaxoSmithKline and Rolls-Royce. 'After an extensive and careful examination I have concluded that there is...